Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BMO-2 vs Humira in Healthy Adults
NCT02472912Phase 1Completed
- Sponsor
- Mylan
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Mylan. Primary endpoint: Area under the plasma concentration versus time curve at 71 days. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02472912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472912.